QST consistently shows altered central pain processing and impaired endogenous inhibition in patients with OUD on OAT, supporting its potential to improve pain mechanism understanding.
An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant ...
GPT-4 variants excel at checking AI trial consistency with CONSORT-AI. Keep reading to see how LLMs are shaping research ...
A meta-analysis shows that physical exercise and mental training improve global cognition in older adults, with their ...
High Efficacy of Fractionated Stereotactic Radiotherapy of Large Base-of-Skull Meningiomas: Long-Term Results PURPOSE: To explore the association at different time points in the trajectory of breast ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The ...
Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices. Electronic patient-reported outcome-based weight management versus usual care ...
The real risk isn't in running robust tests; it’s in wasting money or cutting high-performing channels based on misleading ...
When it comes to trials of any drug, size matters, potentially giving the World Health Organization's (WHO) gloomy verdict on Gilead Sciences' COVID-19 treatment remdesivir an edge over the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback